Get the Stockscreener App
13.59
0.63%
0.08
Gh Research Plc stock is traded at $13.59, with a volume of 334.12K.
It is up +0.63% in the last 24 hours and up +49.23% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
See More
Previous Close:
$13.51
Open:
$13.21
24h Volume:
334.12K
Relative Volume:
0.94
Market Cap:
$702.90M
Revenue:
-
Net Income/Loss:
$-41.43M
P/E Ratio:
-17.20
EPS:
-0.79
Net Cash Flow:
$-39.97M
1W Performance:
+28.26%
1M Performance:
+49.23%
6M Performance:
+27.18%
1Y Performance:
+69.09%
1-Day Range:
$12.56
$13.89
1-Week Range:
$12.04
$20.50
52-Week Range:
$6.00
$20.50
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
13.59 | 702.90M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.44 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
717.60 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.39 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.82 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.86 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
Gh Research Plc Stock (GHRS) Latest News
GH Research (NASDAQ:GHRS) Hits New 1-Year HighShould You Buy? - MarketBeat
GH Research PLC Raises $139.8 Million Through Share Offering - TipRanks
Taking on analysts’ expectations and winning: GH Research PLC (GHRS) - SETE News
GHRS Stock Rallies 55% in a Week: Here's What You Should Know - Yahoo Finance
Financial Metrics Unveiled: GH Research PLC (GHRS)’s Key Ratios in the Spotlight - The Dwinnex
Where are the Opportunities in (GHRS) - Stock Traders Daily
H.C. Wainwright maintains buy on GH Research stock, $40 target - MSN
GH Research PLC (GHRS) stock: A year of ups and downs - US Post News
GH Research (NASDAQ:GHRS) Reaches New 12-Month HighShould You Buy? - MarketBeat
GH Research Secures $150 Million in Public Offering - TipRanks
ForexTV | Small Business Resources - ForexTV.com
Major Biotech Stock Offering: GH Research Secures $150M War Chest Through Share Sale - StockTitan
GH Research Announces Pricing of $150 Million Public Offering - Yahoo Finance
GH Research Announces Pricing of $150 Million Public Offering - GlobeNewswire Inc.
GH Research PLC [GHRS] is 157.00% higher this YTD. Is it still time to buy? - The DBT News
GH Research (NASDAQ:GHRS) Shares Gap UpShould You Buy? - MarketBeat
H.C. Wainwright maintains buy on GH Research stock, $40 target By Investing.com - Investing.com Australia
Why GH Research PLC (GHRS) Is Skyrocketing So Far In 2025 - MSN
GH Research launches $150 million offering - Green Market Report
Shares Soar as GH Research Unveils Promising Drug Trial - Value the Markets
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Healthcare's Hidden Gem: Why GH Research PLC Stock is Surging in 2025! - Jomfruland.net
GH Research stock target raised to $42 at Rodman & Renshaw - Investing.com India
GH Research Announces Primary Endpoint Met in Phase 2b - GlobeNewswire
GH Research stock target raised to $42 at Rodman & Renshaw By Investing.com - Investing.com South Africa
GH Research skyrockets on 5-MeO-DMT drug’s depression treatment breakthrough - Mugglehead
GH’s Phase IIb Data Show Potential Differentiation In Depression - News & Insights
GH Research Announces $150 Million Public Offering Of Ordinary Shares -February 03, 2025 at 05:22 pm EST - Marketscreener.com
GH Research Initiates $150 Million Public Offering to Advance Depression Treatment - TipRanks
SEC Form 424B5 filed by GH Research PLC - Quantisnow
The Significance of Moving Averages in GH Research PLC Inc. (GHRS) Price Performance - The InvestChronicle
GH Research Updates Risk Factors Amid Ongoing Challenges - TipRanks
GH Research Announces Proposed Public Offering - GlobeNewswire
Major Capital Raise: GH Research Launches $150M Share Offering to Accelerate Growth - StockTitan
Crude Oil Moves Higher; Owens & Minor Shares Plummet - Benzinga
GH Research stock hits 52-week high at $19.98 amid growth - MSN
Stock market news: GH Research PLC +85.19%, Reborn Coffee +64.85% among top gainers during mid day trading - Business Upturn
GH Research stock soars on positive Phase 2b trial results - MSN
Dow Falls 150 Points; ISM Manufacturing PMI Rises In January - Benzinga
Shares of psychedelics biotech nearly double on depression data - BioPharma Dive
GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant Depression - Psychedelic Alpha
Why Is GH Research Stock Trading Higher On Monday? - Benzinga
S&P 500 Down Over 1%; Tyson Foods Posts Upbeat Results - Benzinga
Small-Cap Stocks Surge: GH Research, Society Pass and Reborn Coffee Lead Monday Gainers - HPBL
Stock market today: GH Research +79.25%, Reborn Coffee +54.55% amonh top gainers in early trading - Business Upturn
GH Research’s GH001 Shows Promising Results in TRD Phase 2b Trial - TipRanks
GH Research Shares Soar 90% Pre-Bell After Trial of GH001 to Treat Depression Meets All Endpoints - Marketscreener.com
GH Research reports breakthrough in depression treatment - Investing.com
GH Research reports breakthrough in depression treatment By Investing.com - Investing.com UK
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction - Yahoo Finance UK
Why Triumph Group Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket - Benzinga
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):